Clinical Trials Directory

Trials / Conditions / HR-positive, HER2-negative Advanced Breast Cancer

HR-positive, HER2-negative Advanced Breast Cancer

7 registered clinical trials studyying HR-positive, HER2-negative Advanced Breast Cancer — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingDifferent Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative
NCT07285382
wanghaiboPhase 2
RecruitingOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1
RecruitingStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
NCT06950086
TYK Medicines, IncPhase 1 / Phase 2
RecruitingA Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemo
NCT05890287
Tianjin Medical University Cancer Institute and HospitalN/A
RecruitingPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advan
NCT06805812
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano—
UnknownIribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
NCT05335473
Henan Cancer HospitalPhase 1 / Phase 2
CompletedA Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
NCT04796623
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2